760
Views
40
CrossRef citations to date
0
Altmetric
Brief Report

Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature

, &
Pages 381-387 | Received 09 May 2017, Accepted 05 Oct 2017, Published online: 18 Dec 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Jia Chen, Lijuan Pan, Shiqiang Qu, Tiejun Qin, Zhijian Xiao & Zefeng Xu. (2022) Intra-abdominal Streptococcus agalactiae infection associated with myelofibrosis treated with ruxolitinib: a case report of an atypical clinical presentation. Current Medical Research and Opinion 38:3, pages 371-374.
Read now
Ming-hui Duan, Xin-Xin Cao, Long Chang & Dao-bin Zhou. (2021) Risk of hepatitis B virus reactivation following ruxolitinib treatment in patients with myeloproliferative neoplasms. Hematology 26:1, pages 460-464.
Read now

Articles from other publishers (38)

Adeniyi Abraham Adesola, Matei-Alexandru Cozma, Yong-Feng Chen, Bahadar Singh Srichawla & Mihnea-Alexandru Găman. (2023) Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib. World Journal of Hepatology 15:11, pages 1188-1195.
Crossref
Andrea Duminuco, Salvatore Scarso, Alessandra Cupri, Nunziatina Laura Parrinello, Loredana Villari, Grazia Scuderi, Giuliana Giunta, Salvatore Leotta, Giulio Antonio Milone, Giulia Giuffrida, Giuseppe Alberto Palumbo & Giuseppe Milone. (2023) Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients. Journal of Clinical Medicine 12:2, pages 578.
Crossref
Marissa Sjoblom, Haithem Chtioui, Montserrat Fraga, Gregoire Stalder, Francesco Grandoni & Sabine Blum. (2022) Hepatitis B reactivation during ruxolitinib treatment. Annals of Hematology 101:9, pages 2081-2086.
Crossref
Asuka Ogai, Kazuma Yagi, Fumimaro Ito, Hideharu Domoto, Tetsuya Shiomi & Kenko Chin. (2022) Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review. Internal Medicine 61:8, pages 1271-1278.
Crossref
Paul Dalla-Pozza, Maxime Hentzien, Clotilde Allavena, Anne Doe de Maindreville, Kévin Bouiller, Marc-Antoine Valantin, Emmanuel Lafont, Olivia Zaegel-Faucher, Antoine Cheret, Guillaume Martin-Blondel, Laurent Cotte & Firouzé Bani-Sadr. (2022) Progressive multifocal leukoencephalopathy in patients with immunovirological control and at least 6 months of combination antiretroviral therapy. AIDS 36:4, pages 539-549.
Crossref
Emma Paige, Scott J. Abbinga & Monica A. Slavin. 2022. Infectious Complications in Biologic and Targeted Therapies. Infectious Complications in Biologic and Targeted Therapies 391 416 .
Naruemit Sayabovorn, Piriyaporn Chongtrakool & Methee Chayakulkeeree. (2021) Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review. BMC Infectious Diseases 21:1.
Crossref
Daniele Cattaneo & Alessandra Iurlo. (2021) Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors. Frontiers in Immunology 12.
Crossref
Kristen Zeitler, Ripal Jariwala, Sally Alrabaa & Chakrapol Sriaroon. (2021) Disseminated blastomycosis in a patient with polycythemia vera on ruxolitinib. BMJ Case Reports 14:11, pages e243694.
Crossref
Tonia Akoumianaki, Katerina Vaporidi, Eleni Diamantaki, Frédéric Pène, Remi Beau, Mark S. Gresnigt, Marina Gkountzinopulou, Maria Venichaki, Elias Drakos, Jamel El-Benna, George Samonis, Kieu T.T. Le, Vinod Kumar, Dimitrios Georgopoulos, Frank L. van de Veerdonk, Mihai G. Netea, Jean-Paul Latge & Georgios Chamilos. (2021) Uncoupling of IL-6 signaling and LC3-associated phagocytosis drives immunoparalysis during sepsis. Cell Host & Microbe 29:8, pages 1277-1293.e6.
Crossref
Naveen Pemmaraju, Natalie C. Chen & Srdan Verstovsek. (2021) Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America 35:2, pages 409-429.
Crossref
Michail S. Lionakis. 2021. Encyclopedia of Mycology. Encyclopedia of Mycology 803 812 .
Shmuel Shoham & M. Veronica Dioverti Prono. 2021. Emerging Transplant Infections. Emerging Transplant Infections 1183 1206 .
Parvis Sadjadian, Kai Wille & Martin Griesshammer. (2020) Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations. Cancers 12:11, pages 3132.
Crossref
Saman Nematollahi & Veronica Dioverti‐Prono. (2020) Cryptococcal infection in haematologic malignancies and haematopoietic stem cell transplantation. Mycoses 63:10, pages 1033-1046.
Crossref
Marcela V. Maus & Michail S. Lionakis. (2020) Infections associated with the new ‘nibs and mabs’ and cellular therapies. Current Opinion in Infectious Diseases 33:4, pages 281-289.
Crossref
Joshua S. Davis, David Ferreira, Emma Paige, Craig Gedye & Michael Boyle. (2020) Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clinical Microbiology Reviews 33:3.
Crossref
Yael Kusne, Kathryn E Kimes, Fionna F Feller, Roberto Patron, Juan Gea Banacloche, Janis E Blair, Holenarasipur R Vikram & Neil M Ampel. (2020) Coccidioidomycosis in Patients Treated With Ruxolitinib. Open Forum Infectious Diseases 7:6.
Crossref
Esther Benamu. (2020) Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases. Infectious Disease Clinics of North America 34:2, pages 271-310.
Crossref
Yujin Li, Shirong Zhu, Weiyi Liu, Jing Ming, Xueying Wang & Xiaomei Hu. (2020) Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to. Annals of Hematology 99:6, pages 1161-1176.
Crossref
Claire N. Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Eric Jourdan, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Shelonitda Rose, Juan Shen, Tymara Berry, Carrie Brownstein & Ruben A. Mesa. (2020) Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure . American Journal of Hematology 95:6, pages 594-603.
Crossref
Imran Mohamedy & Graeme N. Forrest. (2020) Cryptococcal Immune Reconstitution Inflammatory Syndrome: a Paradoxical Response to a Complex Organism. Current Treatment Options in Infectious Diseases 12:1, pages 13-29.
Crossref
Rebecca E. Schultze‐Florey, Sabine Tischer‐Zimmermann, Hans‐Gert Heuft, Christoph Priesner, Britta Lamottke, Albert Heim, Martin Sauer, Karl‐Walter Sykora, Rainer Blasczyk, Britta Eiz‐Vesper & Britta Maecker‐Kolhoff. (2019) Transfer of Hexon‐ and Penton‐selected adenovirus‐specific T cells for refractory adenovirus infection after haploidentical stem cell transplantation. Transplant Infectious Disease 22:1.
Crossref
Athanasia Tourlaki, Valentina Benzecry, Stefano Veraldi & Lucia Brambilla. (2019) Iatrogenic Kaposi sarcoma in a patient treated with ruxolitinib: A case report. The Journal of Dermatology 47:2.
Crossref
Daisuke Tsukui, Hiroaki Fujita, Keisuke Suzuki & Koichi Hirata. (2020) A case report of cryptococcal meningitis associated with ruxolitinib. Medicine 99:13, pages e19587.
Crossref
Shmuel Shoham & M. Veronica Dioverti Prono. 2020. Emerging Transplant Infections. Emerging Transplant Infections 1 25 .
Shruti Prem, David Loach, Jeffrey Lipton, Rajat Kumar & Vikas Gupta. (2019) EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis. BLOOD RESEARCH 54:4, pages 282-284.
Crossref
Jean-Paul Latgé & Georgios Chamilos. (2019) Aspergillus fumigatus and Aspergillosis in 2019. Clinical Microbiology Reviews 33:1.
Crossref
Katya Prakash & Douglas Richman. (2019) A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib. BMC Infectious Diseases 19:1.
Crossref
Mark S. Godfrey & Lloyd N. Friedman. (2019) Tuberculosis and Biologic Therapies. Clinics in Chest Medicine 40:4, pages 721-739.
Crossref
Katie Bechman, James B Galloway & Kevin L Winthrop. (2019) Small-Molecule Protein Kinases Inhibitors and the Risk of Fungal Infections. Current Fungal Infection Reports 13:4, pages 229-243.
Crossref
Emanuela Sant’Antonio, Massimiliano Bonifacio, Massimo Breccia & Elisa Rumi. (2019) A journey through infectious risk associated with ruxolitinib. British Journal of Haematology 187:3, pages 286-295.
Crossref
Marissa A. Zarakas, Jigar V. Desai, Georgios Chamilos & Michail S. Lionakis. (2019) Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors. Current Fungal Infection Reports 13:3, pages 86-98.
Crossref
Sameem Abedin, Edward McKenna, Saurabh Chhabra, Marcelo Pasquini, Nirav N. Shah, James Jerkins, Arielle Baim, Lyndsey Runaas, Walter Longo, William Drobyski, Parameswaran N. Hari & Mehdi Hamadani. (2019) Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 25:8, pages 1689-1694.
Crossref
Sylvain Lescuyer, Marie-Pierre Ledoux, Simon Gravier, Shanti Natarajan-Amé, Céline Duval, Fréderic Maloisel, Laurent Mauvieux, Elise Toussaint, Luc-Matthieu Fornecker & Raoul Herbrecht. (2019) Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera. International Journal of Infectious Diseases 80, pages 134-136.
Crossref
Amrita Chakrabarti & Nitin Sood. (2018) Cryptococcal meningitis in an immunocompetent patient with primary myelofibrosis on long-term ruxolitinib: report of a rare case and review of literature. memo - Magazine of European Medical Oncology 11:4, pages 348-350.
Crossref
Francesco Passamonti & Margherita Maffioli. (2018) The role of JAK2 inhibitors in MPNs 7 years after approval. Blood 131:22, pages 2426-2435.
Crossref
. (2018) Ruxolitinib. Reactions Weekly 1700:1, pages 233-233.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.